These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 32841584)

  • 1. Co-delivery of a RanGTP inhibitory peptide and doxorubicin using dual-loaded liposomal carriers to combat chemotherapeutic resistance in breast cancer cells.
    Haggag Y; Abu Ras B; El-Tanani Y; Tambuwala MM; McCarron P; Isreb M; El-Tanani M
    Expert Opin Drug Deliv; 2020 Nov; 17(11):1655-1669. PubMed ID: 32841584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast cancer targeted chemotherapy based on doxorubicin-loaded bombesin peptide modified nanocarriers.
    Wang C; Sun X; Wang K; Wang Y; Yang F; Wang H
    Drug Deliv; 2016 Oct; 23(8):2697-2702. PubMed ID: 26203692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipoic acid-derived cross-linked liposomes for reduction-responsive delivery of anticancer drug.
    Ling L; Ismail M; Du Y; Yao C; Li X
    Int J Pharm; 2019 Apr; 560():246-260. PubMed ID: 30769133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-delivery of Poria cocos extract and doxorubicin as an 'all-in-one' nanocarrier to combat breast cancer multidrug resistance during chemotherapy.
    Li Y; Li X; Lu Y; Chaurasiya B; Mi G; Shi D; Chen D; Webster TJ; Tu J; Shen Y
    Nanomedicine; 2020 Jan; 23():102095. PubMed ID: 31669856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual-Functional Peptide Driven Liposome Codelivery System for Efficient Treatment of Doxorubicin-Resistant Breast Cancer.
    Ahmed KS; Liu S; Mao J; Zhang J; Qiu L
    Drug Des Devel Ther; 2021; 15():3223-3239. PubMed ID: 34349500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical study of Doxorubicine-loaded liposomal drug delivery for the treatment of head and neck cancer: Optimization by Box-Behnken statistical design.
    Yang B
    Acta Biochim Pol; 2020 Jun; 67(2):149-155. PubMed ID: 32506868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell-penetrating corosolic acid liposome as a functional carrier for delivering chemotherapeutic drugs.
    Li X; Widjaya AS; Liu J; Liu X; Long Z; Jiang Y
    Acta Biomater; 2020 Apr; 106():301-313. PubMed ID: 32081779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitization of multidrug-resistant malignant cells by liposomes co-encapsulating doxorubicin and chloroquine through autophagic inhibition.
    Gao M; Xu Y; Qiu L
    J Liposome Res; 2017 Jun; 27(2):151-160. PubMed ID: 27250110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversal of P-glycoprotein-mediated multidrug resistance by doxorubicin and quinine co-loaded liposomes in tumor cells.
    Shen Q; Qiu L
    J Liposome Res; 2017 Dec; 27(4):293-301. PubMed ID: 27581212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-delivery of doxorubicin and PSC 833 (Valspodar) by stealth nanoliposomes for efficient overcoming of multidrug resistance.
    Bajelan E; Haeri A; Vali AM; Ostad SN; Dadashzadeh S
    J Pharm Pharm Sci; 2012; 15(4):568-82. PubMed ID: 23106959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted multidrug delivery system to overcome chemoresistance in breast cancer.
    Tang Y; Soroush F; Tong Z; Kiani MF; Wang B
    Int J Nanomedicine; 2017; 12():671-681. PubMed ID: 28176940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy.
    Paliwal SR; Paliwal R; Pal HC; Saxena AK; Sharma PR; Gupta PN; Agrawal GP; Vyas SP
    Mol Pharm; 2012 Jan; 9(1):176-86. PubMed ID: 22091702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T7 peptide-mediated co-delivery platform overcoming multidrug-resistant breast cancer: In vitro and in vivo evaluation.
    Zhang SS; Yu JH; Jiang SS; Wang L; Chen J; Long J; Gu SX; Li H
    Eur J Pharm Biopharm; 2024 Jul; 200():114327. PubMed ID: 38759900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineered breast tumor targeting peptide ligand modified liposomal doxorubicin and the effect of peptide density on anticancer activity.
    Shahin M; Soudy R; Aliabadi HM; Kneteman N; Kaur K; Lavasanifar A
    Biomaterials; 2013 May; 34(16):4089-4097. PubMed ID: 23465829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A smart tumor targeting peptide-drug conjugate, pHLIP-SS-DOX: synthesis and cellular uptake on MCF-7 and MCF-7/Adr cells.
    Song Q; Chuan X; Chen B; He B; Zhang H; Dai W; Wang X; Zhang Q
    Drug Deliv; 2016 Jun; 23(5):1734-46. PubMed ID: 25853477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tuftsin-Bearing Liposomes Co-Encapsulated with Doxorubicin and Curcumin Efficiently Inhibit EAC Tumor Growth in Mice.
    Murugesan K; Srinivasan P; Mahadeva R; Gupta CM; Haq W
    Int J Nanomedicine; 2020; 15():10547-10559. PubMed ID: 33414637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-Eradication of Breast Cancer Cells and Cancer Stem Cells by Cross-Linked Multilamellar Liposomes Enhances Tumor Treatment.
    Kim YJ; Liu Y; Li S; Rohrs J; Zhang R; Zhang X; Wang P
    Mol Pharm; 2015 Aug; 12(8):2811-22. PubMed ID: 26098197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ultrasound-mediated cavitation enhances the delivery of an EGFR-targeting liposomal formulation designed for chemo-radionuclide therapy.
    Thomas E; Menon JU; Owen J; Skaripa-Koukelli I; Wallington S; Gray M; Mannaris C; Kersemans V; Allen D; Kinchesh P; Smart S; Carlisle R; Vallis KA
    Theranostics; 2019; 9(19):5595-5609. PubMed ID: 31534505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-delivery of doxorubicin and P-gp inhibitor by a reduction-sensitive liposome to overcome multidrug resistance, enhance anti-tumor efficiency and reduce toxicity.
    Tang J; Zhang L; Gao H; Liu Y; Zhang Q; Ran R; Zhang Z; He Q
    Drug Deliv; 2016 May; 23(4):1130-43. PubMed ID: 25491241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineered peptides for the development of actively tumor targeted liposomal carriers of doxorubicin.
    Shahin M; Soudy R; El-Sikhry H; Seubert JM; Kaur K; Lavasanifar A
    Cancer Lett; 2013 Jul; 334(2):284-92. PubMed ID: 23073474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.